<DOC>
	<DOCNO>NCT01019577</DOCNO>
	<brief_summary>The purpose study determine response rate Ixabepilone ( BMS-247550 ) subject metastatic breast cancer previously treat anthracycline taxane resistant .</brief_summary>
	<brief_title>Clinical Study Ixabepilone ( BMS-247550 ) Every-3-week Dosing Regimen Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Who Are Taxane Resistant</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Women age 20 year old Patients metastatic breast cancer whose primary lesion definitely diagnose breast histological cellular examination Patients Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) â‰¥ 2</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>